Issue link: http://cp.revolio.com/i/800850
There is no question that men and women who suffer from hormone deficiency (andropause and menopause) do benefit from hormone replacement therapy. However, a one- size-fits-all approach in HRT (synthetic hormones) and BHRT (bioidentical hormones) may provide more harm than good to many patients. It is important to keep in mind that each individual's hormone needs vary and should be addressed accordingly. Even more important, is the knowledge of cancer risks involved with excess hormone accumulation. Among individuals on HRT or BHRT, there needs to be a balance among the different estrogens: estrone (E1), estradiol (E2) and estriol (E3). Studies show that E3, the weak estrogen, becomes an anticarcinogen in the presence of E1 and E2. Henry Lemon, who derived the estrogen quotient: (E3>E1+E2), figured out that an EQ higher than 1 (meaning more E3 than E1 and E2 combined) signals lower cancer risk. MYOMIN for Men and Women on HRT or BHRT to REDUCE CANCER RISK Women need to check their EQ once they hit menopause in order to keep track of estrogen balance. Also if the breasts hurt after menopause, this is a sign of increased breast cancer risk, especially in women on HRT or BHRT. Men and women on any type of hormone therapy will benefit from adding Myomin to their regimen. Always remember that HRT or BHRT carries a risk of hyperaromatization. This happens when the aromatase enzyme converts androgens into excessive estrogens. Androstenedione and testosterone are directly converted to estrone and estradiol, respectively. Progesterone, pregnenolone, and DHEA, on the other hand, are all the precursors of androgens and may also be converted into estrogens. Myomin helps minimize this conversion by reducing aromatase expression. As a result, it counteracts the harmful effects and risks associated with HRT or BHRT. Page 30 | Abby's Magazine - www.AbbysHealthAndNutrition.com